Literature DB >> 25807942

Targeting microRNAs in Pathological Hypertrophy and Cardiac Failure.

Dongchao Lv, Jingqi Liu, Cuimei Zhao, Qi Sun, Qiulian Zhou, Jiahong Xu, Junjie Xiao1.   

Abstract

MicroRNAs (miRNAs) are a novel class of endogenous, short, non-coding, posttranscriptional RNAs, which play important roles in regulating lots of important biological functions. Evidences show that altered expression of miRNAs are involved in pathological hypertrophy and cardiac failure, making it possible to target miRNAs as a novel therapy. In this review, we focus on very recent progresses in the regulation of miRNAs in pathological hypertrophy and cardiac failure. In addition, we also discuss the potential of using miRNAs as a new therapy for pathological hypertrophy and cardiac failure.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25807942     DOI: 10.2174/1389557515666150324124751

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  9 in total

1.  Circulating miR-30d Predicts Survival in Patients with Acute Heart Failure.

Authors:  Junjie Xiao; Rongrong Gao; Yihua Bei; Qiulian Zhou; Yanli Zhou; Haifeng Zhang; Mengchao Jin; Siqi Wei; Kai Wang; Xuejuan Xu; Wenming Yao; Dongjie Xu; Fang Zhou; Jingfa Jiang; Xinli Li; Saumya Das
Journal:  Cell Physiol Biochem       Date:  2017-02-16

2.  MicroRNA-497 Inhibits Cardiac Hypertrophy by Targeting Sirt4.

Authors:  Yimin Xiao; Xiaofei Zhang; Shihao Fan; Guanghao Cui; Zhenya Shen
Journal:  PLoS One       Date:  2016-12-16       Impact factor: 3.240

3.  MicroRNA Expression Signature in Human Calcific Aortic Valve Disease.

Authors:  Hui Wang; Jing Shi; Beibei Li; Qiulian Zhou; Xiangqing Kong; Yihua Bei
Journal:  Biomed Res Int       Date:  2017-04-11       Impact factor: 3.411

Review 4.  Bioinformatics Analysis Reveals MicroRNAs Regulating Biological Pathways in Exercise-Induced Cardiac Physiological Hypertrophy.

Authors:  Jiahong Xu; Yang Liu; Yuan Xie; Cuimei Zhao; Hongbao Wang
Journal:  Biomed Res Int       Date:  2017-02-14       Impact factor: 3.411

5.  ADAR2 increases in exercised heart and protects against myocardial infarction and doxorubicin-induced cardiotoxicity.

Authors:  Xiaoting Wu; Lijun Wang; Kai Wang; Jin Li; Rui Chen; Xiaodong Wu; Gehui Ni; Chang Liu; Saumya Das; Joost P G Sluijter; Xinli Li; Junjie Xiao
Journal:  Mol Ther       Date:  2021-07-16       Impact factor: 11.454

6.  Mechanism underlying increased cardiac extracellular matrix deposition in perinatal nicotine-exposed offspring.

Authors:  Tsai-Der Chuang; Aamir Ansari; Celia Yu; Reiko Sakurai; Amir Harb; Jie Liu; Omid Khorram; Virender K Rehan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-08-14       Impact factor: 5.125

7.  miR-19b controls cardiac fibroblast proliferation and migration.

Authors:  Chongjun Zhong; Kun Wang; Ying Liu; Dongchao Lv; Bo Zheng; Qiulian Zhou; Qi Sun; Ping Chen; Shengguang Ding; Yiming Xu; Haitao Huang
Journal:  J Cell Mol Med       Date:  2016-04-06       Impact factor: 5.310

8.  MicroRNA Expression Signature in Degenerative Aortic Stenosis.

Authors:  Jing Shi; Hui Liu; Hui Wang; Xiangqing Kong
Journal:  Biomed Res Int       Date:  2016-08-04       Impact factor: 3.411

9.  Molecular mechanisms in microRNA-mediated TRB3 gene and hypertension left ventricular hypertrophy.

Authors:  Jun-Yi Zeng; Juan Lei; Yun-Feng Wei; Ze-Qi Zheng; Wan Zhang; Yong-Nan Fu; Tong Wen; Da-Song Yi; Lu Ding
Journal:  Exp Ther Med       Date:  2017-03-10       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.